J&J myeloma drug combo shows survival gains in Phase 3 data

September 23, 2026 9:47 AM

Johnson & Johnson (NYSE: JNJ) released new data from the Phase 3 MajesTEC-3 study showing survival outcomes for a combination ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found